These conditions may be exacerbated by glutamine supplementation, making their management more complex
The method of Priority Applications (1) Applications Claiming Priority (4) Related Parent Applications (1) Publications (1) Family ID=35759146 Family Applications (4) Family Applications Before (3) Country Status (14) Cited By (1) Families Citing this family (9) Family Cites Families (32) 2004 2004-11-17 US US10/990,933 patent/US20060105972A1/en not_active Abandoned 2005 2005-11-16 KR KR1020077013535A patent/KR20070095900A/en not_active Ceased 2005-11-16 WO PCT/US2005/041458 patent/WO2006055597A1/en not_active Ceased 2005-11-16 BR BRPI0516814-7A patent/BRPI0516814A/en not_active IP Right Cessation 2005-11-16 DK DK05823154.9T patent/DK1824481T3/en active 2005-11-16 AU AU2005307885A patent/AU2005307885B2/en not_active Ceased 2005-11-16 CN CNA2005800393226A patent/CN101060840A/en active Pending 2005-11-16 EP EP05823154A patent/EP1824481B1/en not_active Expired - Lifetime 2005-11-16 JP JP2007543186A patent/JP2008520681A/en active Pending 2005-11-16 PL PL05823154T patent/PL1824481T3/en unknown 2005-11-16 MX MX2007005835A patent/MX2007005835A/en unknown 2005-11-16 EA EA200701017A patent/EA014076B1/en not_active IP Right Cessation 2005-11-16 CA CA2587616A patent/CA2587616C/en not_active Expired - Fee Related 2005-11-16 ES ES05823154T patent/ES2390228T3/en not_active Expired - Lifetime 2008 2008-07-30 US US12/182,354 patent/US8501700B2/en active Active 2013 2013-08-02 US US13/958,530 patent/US9144570B2/en not_active Expired - Lifetime 2015 2015-08-27 US US14/838,274 patent/US20160082029A1/en not_active Abandoned
Those with medium dark to dark skin typically require 8 treatments
Report suspected adverse reactions : If you experience any unexpected symptoms or side effects after taking a supplement, you can report these via the MHRA Yellow Card scheme (available at yellowcard
Clinical Efficacy and Research Results Clinical registries and neurological guidelines (20202026) strongly emphasize the urgency of B12 replacement to prevent permanent paralysis or irreversible nerve death
A: Early animal data is promising, but human cartilage regeneration remains under investigation
